March 11th New York Security Conference Agenda: Learn about Cybersecurity, Biometrics, Biodefense, Explosive Detection from Industry and Financial Experts, Publicly Traded and Private Companies

New York, NY - March 10, 2014 (www.investorideas.com newswire) Investorideas.com, an investor research and news portal covering leading sectors including technology and defense announces the agenda and speakers for the Security and Defense Conference, “Game Changing Technologies: The Face and Future of Security”, to be held both live in New York and online on March 11, 2014.

The conference is free to attend but donations are welcomed to Federal Enforcement Homeland Security Foundation. The Federal Enforcement Homeland Security Foundation is a Non-Profit 501 c (3) Corporation formed to assist the Federal Law Enforcement Community (ATF, CBP, DEA, FAMS, FBI, ICE, Secret Service, U S Marshal's) and their families in times of need especially related to Line of Duty deaths along with health or medical issues involving family members. Our Country needs these courageous men and women who wear the uniform in our ongoing fight against domestic and international terrorism and in the general enforcement of our Country's Laws. www.fehsf.org
When /where:
Tuesday, March 11, 2014, The New York Hilton Midtown, New York City (1335 Avenue of the Americas, New York, NY 10019) and Online.
Conference info:
http://www.investorideas.com/Conference/

Media, Investors, Service Providers Attend and Register free: http://www.investorideas.com/Conference/Conference-Registration.asp

Agenda for Tuesday, March 11:

8:00 – 9:00AM	Registration & Networking
9:00 - 9:20AM	What is the Key to Staying Ahead?
Featured Speaker: MICHAEL BALBONI, Former New York State Senator; Founder RedLand Strategies, Inc.
9:20 – 9:35AM	Welcome & Opening Remarks
SPEAKER: RICHARD KENDALL, Federal Enforcement Homeland Security Foundation
9:35 – 10:25AM	Game Changing Technologies: The Face and Future of Security

See full agenda at http://www.investorideas.com/Conference/
The technology of authentication, biometrics, biodefense, cyber security, drones, nanotechnology and unmanned aerial vehicles (UAV) is evolving faster than we think. This panel of industry experts discusses the current state of the security and defense industry, and explores where it's headed in 2014 and beyond.
MODERATOR: ROGER CRESSEY, Liberty Group Ventures
PANELISTS: SCOTT GREIPER, Secure Strategy Group; MARTY MARTIN, Crane & Crane Consulting; JANICE KEPHART, The Secure Identity and Biometrics Association (SIBA)

10:30 – 10:55AM	Applied DNA Sciences, Inc. (APDN)
11:00 – 11:25AM	Viscount Systems (OTCQB: VSYS)
11:30 – 11:55AM	American Public University System (NASDAQ: APEI)
12:00 – 12:25PM	NXT-ID (OTCQB: NXTD)
12:30 – 1:00PM	Exploring the NIST Cybersecurity Framework and Implementation

Under Executive Order, President Obama directed The National Institute of Standards and Technology (NIST) to "work with stakeholders to develop a voluntary framework for reducing cyber risks to critical infrastructure." Kiersten Todt and Roger Cressey supported the NIST in drafting the Cybersecurity framework and soliciting input from the private sector. This session explores the framework, its implementation in key critical infrastructure sectors, and the impact of these cybersecurity policies on the industry and emerging businesses. SPEAKERS: KIERSTEN TODT & ROGER CRESSEY, Liberty Group Ventures

1:00 – 2:00PM	Lunch Break (Attendees are responsible for their own lunches)
2:00 – 2:55PM	Performance and Investing opportunities in Security and Defense Companies

This panel of financial experts examines recent trends on the financial landscape of the industry, the performance of various investment opportunities in the sector, and how to position your company properly for investment and growth.
MODERATOR: SCOTT GREIPER, Secure Strategy Group
PANELISTS: SCOTT SACKNOFF, SPADE Indexes; KRIS TUTTLE, Soundview Technology Group; MANISH THAKUR, Hudson Fairfax Group; PHIL AGCAOLI, Cloud Security Alliance

3:00 – 3:25PM	Tekcapital, Ltd.
3:30 – 3:55PM	PositiveID Corporation (OTCBB: PSID)
4:00 – 4:25PM	Networking Break
4:30 – 4:55PM	Implant Sciences (OTCQB: IMSC)
5:00 – 5:25PM	Silanis Technology
5:30PM	Closing Remarks
SPEAKER: LESTER QUINTANA, Cellucci Associates, Inc.
5:45 – 7:15PM	Cocktail Reception

Media Partners:
Media partners include www.SecuritySolutionsWatch.com , a breaking news site covering new security solutions and business trends; SecurityStockWatch.com for investors following the sector; www.Wallstreetcalendar.com , informing the institutional investment community; Australian Security Magazine ( http://www.australiansecuritymagazine.com.au/ ); Global Security Finance ( www.globalsecurityfinance.com ), an online daily news and data service covering the physical, cyber and identity security and defense sectors; Hedge Connection ( https://www.hedgeconnection.com ), an interactive, web-based marketing tool available to hedge funds and investors; www.biometricupdate.com and http://www.biometricstechnologywatch.com/.
About InvestorIdeas.com: www.investorideas.com
InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense and security, renewable energy, food and beverage stocks and Latin American stocks.
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894 . Global investors must adhere to regulations of each country
Presenting Companies Contact info:
Cali Van Zant cvanzant@investorideas.com 800. 665. 0411
Sponsorship info:
Eric Salvarezza esalvarezza@investorideas.com 631. 664. 1311
Media Partners: D. Van Zant dvanzant@investorideas.com 800. 665. 0411
800-665-0411 - Source: www.Investorideas.com

New York Defense and Security Conference Features Session on "Exploring the NIST Cybersecurity Framework and Implementation"

New York, NY - March 6, 2014 (www.investorideas.com newswire) Investorideas.com, an investor research and news portal covering leading sectors including technology and defense announces cybersecurity sessions and industry panelists for its upcoming Security and Defense Conference, "Game Changing Technologies: The Face and Future of Security", to be held both live in New York and online in recorded video on March 11, 2014.

As cybersecurity becomes a leading concern for corporations and Government, the expertise on the industry panel in the morning session will provide insight into this and other leading security issues.
9:35 - 10:25AM
MODERATOR: ROGER CRESSEY, Liberty Group Ventures
PANELISTS: SCOTT GREIPER, Secure Strategy Group; MARTY MARTIN, Crane & Crane Consulting; JANICE KEPHART, The Secure Identity and Biometrics Association (SIBA)
Exploring the NIST Cybersecurity Framework and Implementation- 12:30 - 1:00PM
Under Executive Order, President Obama directed The National Institute of Standards and Technology (NIST) to "work with stakeholders to develop a voluntary framework for reducing cyber risks to critical infrastructure." Kiersten Todt and Roger Cressey supported the NIST in drafting the Cybersecurity framework and soliciting input from the private sector. This session explores the framework, its implementation in key critical infrastructure sectors, and the impact of these cybersecurity policies on the industry and emerging businesses. SPEAKERS: KIERSTEN TODT & ROGER CRESSEY, Liberty Group Ventures
The theme of the conference is 'Game Changing Technologies: The Face and Future of Security' and will be discussing developments in biodefense, biometrics including fingerprint, voice and facial recognition, cyber security and other leading edge technologies. Speakers and presenters will discuss how these issues impact individuals, corporations and governments globally.
Michael Balboni, Former New York State Senator and Founder of RedLand Strategies, Inc. will open the conference agenda at 9:00 a.m. following networking and registration. Mr. Balboni was First Chairman of the Senate Homeland Security Committee and as NYS Senator wrote nearly all of the major laws relating to Homeland Security for New York State.
Closing the conference is Mr. Lester Quintana, Senior Vice President for Consulting Services, Cellucci Associates, Inc. Mr. Quintana is a dynamic high-technology Business Executive with a strategic business and tactical operations background; he has held key positions in the Department of Defense, Department of Homeland Security, and other agencies. He has been engaged in Russia, States of the Former Soviet Union, Kuwait, Iraq, and globally sensitive locations.
The conference is free to attend but donations are welcomed to Federal Enforcement Homeland Security Foundation. The Federal Enforcement Homeland Security Foundation is a Non-Profit 501 c (3) Corporation formed to assist the Federal Law Enforcement Community (ATF, CBP, DEA, FAMS, FBI, ICE, Secret Service, U S Marshal's) and their families in times of need especially related to Line of Duty deaths along with health or medical issues involving family members. Our Country needs these courageous men and women who wear the uniform in our ongoing fight against domestic and international terrorism and in the general enforcement of our Country's Laws.
FEHSF supports the men and women in Federal Law Enforcement who provide the front line of defense who dedicate themselves to the protection and preservation of our way of life, upholding the laws of our country and protecting our citizens and borders. Aside from the Foundation's Grants Program providing financial assistance often within 24 hours, the Foundation has also established a College Education Fund to benefit children left behind. Our friends in Federal Law Enforcement need us and they deserve our support. We are honored to serve them. www.fehsf.org
When /where:
Tuesday, March 11, 2014, The New York Hilton Midtown, New York City (1335 Avenue of the Americas, New York, NY 10019) and Online. (Video will be available all day plus archived).
Conference info:
http://www.investorideas.com/Conference/

Media, Investors, Service Providers Attend and Register free: http://www.investorideas.com/Conference/Conference-Registration.asp

Agenda:

8:00 – 9:00AM	Registration & Networking
9:00 - 9:20AM	What is the Key to Staying Ahead?
Featured Speaker: MICHAEL BALBONI, Former New York State Senator; Founder RedLand Strategies, Inc.
Full day of speakers and presenting companies followed by:
5:30PM	Closing Remarks SPEAKER: LESTER QUINTANA, Cellucci Associates, Inc.
5:45 – 7:15PM	Cocktail Reception

See full agenda at http://www.investorideas.com/Conference/
Presenting Companies: Publicly traded and private companies in the sector
See the list here: http://www.investorideas.com/Conference/Companies.asp
Speakers: http://www.investorideas.com/Conference/Speakers.asp
The growing list of speakers and presenters includes Michael Balboni, Former New York State Senator and Founder of RedLand Strategies, Mr. Lester Quintana, Senior Vice President for Consulting Services, Cellucci Associates, Inc., Kris Tuttle, Director of Research for SoundView Technology Group; cybersecurity expert and counterterrorism analyst Roger Cressey*, Partner with Liberty Group Ventures; and Kiersten Todt**, President and Managing Partner of Liberty Group Ventures.
*From 2004 - 2013, Roger Cressey served as an on-air counterterrorism analyst with NBC News, appearing frequently on NBC Nightly News, The Today Show, MSNBC and CNBC.
**Ms. Todt has commented on homeland security and sport security issues in multiple media outlets, including MSNBC, NPR, Bloomberg, and The Wall Street Journal. Her work on sport security has been published in two editions of The International Centre for Sport Security Journal.
Other speakers include Jason Kolbert, Head of Healthcare Research, Senior Managing Director and Biotechnology Analyst, Maxim Group; Manish Thakur, Managing Partner of Hudson Fairfax Group;
Marty Martin, CEO of Crane & Crane Consulting, who also has a background with the CIA, NSA, and the U.S. Army; Scott Greiper, President and Founding Partner of Secure Strategy Group; Scott Sacknoff, President of Spade Defense Index (NYSE: ^DXS); Janice Kephart, Founder and CEO of The Secure Identity and Biometrics Association (SIBA) and Phil Agcaoili, Chairman, Ponemon Institute Fellows Co-founding Member, Cloud Security Alliance Board Member, Mobile Active Defense.
Visit the conference page to learn more and sign up:
http://www.investorideas.com/Conference
Investors, media and industry service providers: Register here free: http://www.investorideas.com/Conference/Conference-Registration.asp
Media Partners:
Media partners include www.SecuritySolutionsWatch.com , a breaking news site covering new security solutions and business trends; SecurityStockWatch.com for investors following the sector; www.Wallstreetcalendar.com , informing the institutional investment community; Australian Security Magazine ( http://www.australiansecuritymagazine.com.au/ ); Global Security Finance ( www.globalsecurityfinance.com ), an online daily news and data service covering the physical, cyber and identity security and defense sectors; Hedge Connection ( https://www.hedgeconnection.com ), an interactive, web-based marketing tool available to hedge funds and investors; www.biometricupdate.com and http://www.biometricstechnologywatch.com/.
About InvestorIdeas.com: www.investorideas.com
InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense and security, renewable energy, food and beverage stocks and Latin American stocks.
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894 . Global investors must adhere to regulations of each country
Presenting Companies Contact info:
Cali Van Zant cvanzant@investorideas.com 800. 665. 0411
Sponsorship info:
Eric Salvarezza esalvarezza@investorideas.com 631. 664. 1311
Media Partners: D. Van Zant dvanzant@investorideas.com 800. 665. 0411
800-665-0411 - Source: www.Investorideas.com

New York Defense and Security Conference Adds Speakers from (NASDAQ:APEI), (OTCQB: IMSC), (OTCQB: APDN) Discussing Cybersecurity, Explosives Detection and DNA Based Security

New York, NY - March 5, 2014 (www.investorideas.com newswire) Defense and Security News Alert: Investorideas.com, an investor research and news portal covering leading sectors including technology and defense, announces new speakers and presenters for its upcoming Security and Defense Conference, “Game Changing Technologies: The Face and Future of Security”, to be held both live in New York and online on March 11, 2014.

Added presenting companies includeAmerican Public University System ( NASDAQ:APEI ) speaking on their behalf Dr. Clay Wilson, Program Director for Cybersecurity; Implant Sciences ( OTCQB:IMSC ) a leader in next generation Explosives Trace Detection (ETD) and established counter-terrorism technology and Applied DNA Sciences ( OTCQB: APDN ) ,a provider of botanical-DNA based security and authentication solutions.
Michael Balboni, Former New York State Senator and Founder of RedLand Strategies, Inc. will open the conference agenda at 9:00 a.m. following networking and registration. Mr. Balboni was First Chairman of the Senate Homeland Security Committee and as NYS Senator wrote nearly all of the major laws relating to Homeland Security for New York State.
Closing the conference is Mr. Lester Quintana, Senior Vice President for Consulting Services, Cellucci Associates, Inc. Mr. Quintana is a dynamic high-technology Business Executive with a strategic business and tactical operations background; he has held key positions in the Department of Defense, Department of Homeland Security, and other agencies. He has been engaged in Russia, States of the Former Soviet Union, Kuwait, Iraq, and globally sensitive locations.
The theme of the conference is ‘Game Changing Technologies: The Face and Future of Security’ and will be discussing developments in biodefense, biometrics including fingerprint, voice and facial recognition, cyber security and other leading edge technologies. Speakers and presenters will discuss how these issues impact individuals, corporations and governments globally.
The one-day agenda will include a financial panel, an industry panel that includes some of the brightest minds within the sector, and presenting companies showcasing their innovative technologies. Attendance to this conference is free to all media, investors and industry service providers.
When /where:
Tuesday, March 11, 2014, The New York Hilton Midtown, New York City (1335 Avenue of the Americas, New York, NY 10019) and Online.
Conference info:
http://www.investorideas.com/Conference/

Media, Investors, Service Providers Attend and Register free: http://www.investorideas.com/Conference/Conference-Registration.asp

Agenda:

8:00 – 9:00AM	Registration & Networking
9:00 - 9:20AM	What is the Key to Staying Ahead?
Featured Speaker: MICHAEL BALBONI, Former New York State Senator; Founder RedLand Strategies, Inc.
Full day of speakers and presenting companies followed by:
5:30PM	Closing Remarks SPEAKER: LESTER QUINTANA, Cellucci Associates, Inc.
5:45 – 7:15PM	Cocktail Reception

See full agenda at http://www.investorideas.com/Conference/
Presenting Companies:
See the list here: http://www.investorideas.com/Conference/Companies.asp
New Presenting Company:
American Public University System (NASDAQ:APEI) - Dr. Clay Wilson is the Program Director for Cybersecurity
Dr. Clay Wilson is the Program Director for Cybersecurity graduate studies at the American Public University, where he has responsibility for designing new courses. He is past Program Director for Cybersecurity Policy at the University of Maryland University College (UMUC), where he oversaw development of new graduate-level courses. Dr. Wilson is also a former analyst for national defense policy at the Congressional Research Service where he analyzed cyber intelligence reports for the U.S. Congress and NATO committees on net-centric warfare, cybersecurity, nanotechnology, and other vulnerabilities of high-technology military systems and critical infrastructures. More info: http://www.apu.apus.edu/academic/faculty-members/bio/4438/clay-wilson
Implant Sciences ( OTCQB:IMSC ) is the leader in next generation Explosives Trace Detection (ETD) and established counter-terrorism technology that detects and identifies threats from the small amounts left behind after a person handles explosives. Implant Sciences' security solutions are used worldwide for aviation, public transport, customs, air cargo, critical infrastructure, ports/ borders, and emergency response. The Company has thousands of units deployed to over 50 countries, and its trace detectors have been successfully used at the Sochi Olympics, Beijing Olympics, the Universiade Games, and the Special Olympics.
In January 2013, IMSC became only the third ETD manufacturer and the sole American-owned company to have product approval from the US Transportation Security Administration. With advanced capabilities including superior sensitivity, automatic internal calibration, rapid clear-down, push button maintenance, and administration of trace detection, the Company's handheld QS-H150 and desktop QS-B220 simplify the use, maintenance, and administration of trace detection. www.implantsciences.com
Applied DNA Sciences ( OTCQB: APDN ) is a provider of botanical-DNA based security and authentication solutions that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature(R) DNA describes the uncopyable marker that is at the heart of all of the Company’s security and authentication solutions. SigNature DNA is at the core of a family of products such as DNANet, APDN’s antitheft product, and digitalDNA, which provides powerful track and trace. All provide a forensic chain of evidence and can be used to prosecute perpetrators. www.adnas.com
Speakers: http://www.investorideas.com/Conference/Speakers.asp
The growing list of speakers and presenters includes Michael Balboni, Former New York State Senator and Founder of RedLand Strategies, Mr. Lester Quintana, Senior Vice President for Consulting Services, Cellucci Associates, Inc., Kris Tuttle, Director of Research for SoundView Technology Group; cybersecurity expert and counterterrorism analyst Roger Cressey*, Partner with Liberty Group Ventures; and Kiersten Todt**, President and Managing Partner of Liberty Group Ventures.
*From 2004 - 2013, Roger Cressey served as an on-air counterterrorism analyst with NBC News, appearing frequently on NBC Nightly News, The Today Show, MSNBC and CNBC.
**Ms. Todt has commented on homeland security and sport security issues in multiple media outlets, including MSNBC, NPR, Bloomberg, and The Wall Street Journal. Her work on sport security has been published in two editions of The International Centre for Sport Security Journal.
Other speakers include Jason Kolbert, Head of Healthcare Research, Senior Managing Director and Biotechnology Analyst, Maxim Group; Manish Thakur, Managing Partner of Hudson Fairfax Group;
Marty Martin, CEO of Crane & Crane Consulting, who also has a background with the CIA, NSA, and the U.S. Army; Scott Greiper, President and Founding Partner of Secure Strategy Group; Scott Sacknoff, President of Spade Defense Index (NYSE: ^DXS); Janice Kephart, Founder and CEO of The Secure Identity and Biometrics Association (SIBA) and Phil Agcaoili, Chairman, Ponemon Institute Fellows Co-founding Member, Cloud Security Alliance Board Member, Mobile Active Defense.
Visit the conference page to learn more and sign up:
http://www.investorideas.com/Conference
Investors, media and industry service providers: Register here free: http://www.investorideas.com/Conference/Conference-Registration.asp
Media Partners:
Media partners include www.SecuritySolutionsWatch.com , a breaking news site covering new security solutions and business trends; SecurityStockWatch.com for investors following the sector; www.Wallstreetcalendar.com , informing the institutional investment community; Australian Security Magazine ( http://www.australiansecuritymagazine.com.au/ ); Global Security Finance ( www.globalsecurityfinance.com ), an online daily news and data service covering the physical, cyber and identity security and defense sectors; Hedge Connection ( https://www.hedgeconnection.com ), an interactive, web-based marketing tool available to hedge funds and investors; www.biometricupdate.com and http://www.biometricstechnologywatch.com/.
About InvestorIdeas.com: www.investorideas.com
InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense and security, renewable energy, food and beverage stocks and Latin American stocks.
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894 . Global investors must adhere to regulations of each country
Presenting Companies Contact info:
Cali Van Zant cvanzant@investorideas.com 800. 665. 0411
Sponsorship info:
Eric Salvarezza esalvarezza@investorideas.com 631. 664. 1311
Media Partners: D. Van Zant dvanzant@investorideas.com 800. 665. 0411
800-665-0411 - Source: www.Investorideas.com

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) and Exosome Sciences Announce Brain Research Discoveries

SAN DIEGO - March 5, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that its researchers have successfully isolated brain-specific biomarkers associated with a variety of neurodegenerative disorders. The discoveries could have implications in the diagnosis, monitoring and treatment of Alzheimer's Disease (AD), Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI). Aethlon Medical develops therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions. ESI develops exosome-based solutions to diagnose and monitor acute and chronic conditions.

The research studies provided evidence that exosomes can serve as a "liquid biopsy" to diagnose neurologic conditions. While exosomes from the central nervous system have previously been identified in the cerebrospinal fluid, the Aethlon-ESI study identified exosomes carrying brain-specific markers tau, beta-amyloid, glycoprotein A2B5 and S100B protein in the peripheral circulation of affected individuals. The discoveries provide a basis for an exosome-based platform that could enable the simultaneous identification of multiple brain specific markers that are transported across the blood-brain barrier and into the circulatory system.
CTE is a progressive degenerative disease, which at present can only be definitively diagnosed postmortem. CTE has been most commonly found at autopsy in former professional football players and has also been demonstrated to be prevalent in soldiers exposed to blast injury. The hallmark of CTE is the accumulation of tau, an abnormal protein that strangles brains cells in areas that control memory, emotions and other functions. TBI or repetitive brain trauma, including concussions and sub-concussive blows to the head contribute to the onset of CTE.
AD is the most common form of dementia. There is no cure for the disease, which worsens as it progresses, and eventually leads to death. Beta-amyloid plaques and neurofibrillary tangles have long been recognized as a common pathologic hallmark of AD. In 2010, it was estimated that 36 million people worldwide were living with AD.
"This advancement represents a new paradigm for brain injuries. In addition to providing definitive diagnosis, the proteomic and transcriptomic characterization of exosomes isolated specifically from the brain will provide a window into the molecular mechanisms underlying acute and chronic brain injuries," stated ESI Chief Scientific Officer, Dr. Douglas Taylor.
As a result of the discoveries, brain-derived exosomes can be specifically isolated and the protein and RNA cargoes identified. In studies of brain tissue, specific RNAs have been associated with development of neurological disorders, contributing to the onset and progression of brain injuries. Exosomal RNA and protein cargoes represent surrogates to brain biopsies and have utility as stable, clinically accessible biomarkers for brain injury detection, stratification of patients and therapeutic outcomes.
"With the exosome-based technologies developed by our group, we are at the verge of breakthroughs for the management and treatment of brain injuries and diseases that have been associated with disability and death," stated Dr. Cicek Gercel-Taylor, Clinical Research Director at ESI.
Circulating biomarkers have been proposed for the definitive diagnosis and monitoring treatment of brain injuries. The approach would enable diagnosing the condition, identifying processes that are difficult to image, monitoring responses to interventions, and predicting those who are at risk for long-term neurologic consequences. However, circulating biomarkers such as free protein and nucleic acids are extremely unstable in circulation, thus a high steady-state must be reached for detection, which is generally not observed except in severe cases. To circumvent these issues, exosome-associated biomarkers can be utilized as they are stable and detectable in the circulation.
"An exosome-based liquid biopsy that could identify the early onset of Alzheimer's disease or CTE in a living person may also unlock the ability to monitor disease progression and set the stage for new therapeutic advances, which could include Aethlon Medical therapeutic devices," stated Jim Joyce, CEO of Aethlon Medical and Executive Chairman at Exosome Sciences.
Therapeutic Application and Patent Application
The development of a therapeutic device that targets selective elimination of circulating beta-amyloid and tau is supported by the "peripheral sink" theory, which postulates that the reduction of these particles from systemic circulation promotes deplaquing from the brain. Thus, inhibiting the continued progression of neurodegenerative processes. Aethlon and ESI further disclosed the subsequent filing of a provisional patent entitled, "Brain Specific Exosome Based Diagnostics and Extracorporeal Therapies."
About Aethlon Medical, Inc.
Aethlon Medical creates innovative medical devices to address life-threatening diseases. The Aethlon ADAPT™ (Adaptive Dialysis-like Affinity Platform Technology) establishes the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory system of treated patients. The lead Aethlon ADAPT™ product is the Hemopurifier®, a device that addresses a broad-spectrum of viral pathogens as well as tumorsecreted exosomes that suppress the immune system of cancer patients. Aethlon is also operating under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing exosome-based strategies to diagnose and monitor cancer and infectious disease progression. Additional information can be found at www.AethlonMedical.com
About Exosome Sciences, Inc.
Exosome Sciences (ESI), a majority wholly owned subsidiary of Aethlon Medical, Inc., develops exosome-based solutions to improve identification and monitoring of acute and chronic conditions. Our candidate products are focused toward diagnostic advancements in the fields of oncology, infectious disease and brain injury. Exosomes represent an optimal diagnostic target as diseased or injured cells release these particles into body fluids such as urine, blood, saliva and cerebrospinal fluid where they can be accessed for analysis. Our exosome-based assays unlock the ability to identify proteomic and genomic alterations underlying a wide-range of pathologies, thus allowing for the introduction of novel non-invasive "liquid biopsies". Additional information can be found at www.ExosomeSciences.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's existing or future clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: 2425 quarterly for annual news publishing only starting Feb 26th 2014
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar

Investorideas.com Security Conference Adds Dr. Clay Wilson, Program Director for Cybersecurity at American Public University System (NASDAQ:APEI), Implant Sciences (OTCQB: IMSC)

New York, NY - March 4, 2014 (www.investorideas.com newswire) Investorideas.com, an investor research and news portal covering leading sectors including technology and defense, announces new speakers and presenters for its upcoming Security and Defense Conference, “Game Changing Technologies: The Face and Future of Security”, to be held both live in New York and online on March 11, 2014.

Added presenting companies include American Public University System ( NASDAQ:APEI ) speaking on their behalf Dr. Clay Wilson, Program Director for Cybersecurity; Implant Sciences ( OTCQB:IMSC ) a leader in next generation Explosives Trace Detection (ETD) and established counter-terrorism technology.
Michael Balboni, Former New York State Senator and Founder of RedLand Strategies, Inc. will open the conference agenda at 9:00 a.m. following networking and registration. Mr. Balboni was First Chairman of the Senate Homeland Security Committee and as NYS Senator wrote nearly all of the major laws relating to Homeland Security for New York State.
Closing the conference is Mr. Lester Quintana, Senior Vice President for Consulting Services, Cellucci Associates, Inc. Mr. Quintana is a dynamic high-technology Business Executive with a strategic business and tactical operations background; he has held key positions in the Department of Defense, Department of Homeland Security, and other agencies. He has been engaged in Russia, States of the Former Soviet Union, Kuwait, Iraq, and globally sensitive locations.
The theme of the conference is ‘Game Changing Technologies: The Face and Future of Security’ and will be discussing developments in biodefense, biometrics including fingerprint, voice and facial recognition, cyber security and other leading edge technologies. Speakers and presenters will discuss how these issues impact individuals, corporations and governments globally.
The one-day agenda will include a financial panel, an industry panel that includes some of the brightest minds within the sector, and presenting companies showcasing their innovative technologies. Attendance to this conference is free to all media, investors and industry service providers.
This is one of the best represented conferences in terms of industry expertise, sector knowledge and innovation and will be game-changing for everyone that attends.
When /where:
Tuesday, March 11, 2014, The New York Hilton Midtown, New York City (1335 Avenue of the Americas, New York, NY 10019) and Online.
Conference info:
http://www.investorideas.com/Conference/

Media, Investors, Service Providers Attend and Register free: http://www.investorideas.com/Conference/Conference-Registration.asp

Agenda:

8:00 – 9:00AM	Registration & Networking
9:00 - 9:20AM	What is the Key to Staying Ahead?
Featured Speaker: MICHAEL BALBONI, Former New York State Senator; Founder RedLand Strategies, Inc.
Full day of speakers and presenting companies followed by:
5:30PM	Closing Remarks SPEAKER: LESTER QUINTANA, Cellucci Associates, Inc.
5:45 – 7:15PM	Cocktail Reception

See full agenda at http://www.investorideas.com/Conference/
New Presenting Company:
American Public University System (NASDAQ:APEI) - Dr. Clay Wilson is the Program Director for Cybersecurity
Dr. Clay Wilson is the Program Director for Cybersecurity graduate studies at the American Public University, where he has responsibility for designing new courses. He is past Program Director for Cybersecurity Policy at the University of Maryland University College (UMUC), where he oversaw development of new graduate-level courses. Dr. Wilson is also a former analyst for national defense policy at the Congressional Research Service where he analyzed cyber intelligence reports for the U.S. Congress and NATO committees on net-centric warfare, cybersecurity, nanotechnology, and other vulnerabilities of high-technology military systems and critical infrastructures. More info: http://www.apu.apus.edu/academic/faculty-members/bio/4438/clay-wilson
Implant Sciences ( OTCQB:IMSC ) is the leader in next generation Explosives Trace Detection (ETD) and established counter-terrorism technology that detects and identifies threats from the small amounts left behind after a person handles explosives. Implant Sciences' security solutions are used worldwide for aviation, public transport, customs, air cargo, critical infrastructure, ports/ borders, and emergency response. The Company has thousands of units deployed to over 50 countries, and its trace detectors have been successfully used at the Sochi Olympics, Beijing Olympics, the Universiade Games, and the Special Olympics.
In January 2013, IMSC became only the third ETD manufacturer and the sole American-owned company to have product approval from the US Transportation Security Administration. With advanced capabilities including superior sensitivity, automatic internal calibration, rapid clear-down, push button maintenance, and administration of trace detection, the Company's handheld QS-H150 and desktop QS-B220 simplify the use, maintenance, and administration of trace detection. www.implantsciences.com
Speakers: http://www.investorideas.com/Conference/Speakers.asp
The growing list of speakers and presenters includes Michael Balboni, Former New York State Senator and Founder of RedLand Strategies, Mr. Lester Quintana, Senior Vice President for Consulting Services, Cellucci Associates, Inc., Kris Tuttle, Director of Research for SoundView Technology Group; cybersecurity expert and counterterrorism analyst Roger Cressey*, Partner with Liberty Group Ventures; and Kiersten Todt**, President and Managing Partner of Liberty Group Ventures.
*From 2004 - 2013, Roger Cressey served as an on-air counterterrorism analyst with NBC News, appearing frequently on NBC Nightly News, The Today Show, MSNBC and CNBC.
**Ms. Todt has commented on homeland security and sport security issues in multiple media outlets, including MSNBC, NPR, Bloomberg, and The Wall Street Journal. Her work on sport security has been published in two editions of The International Centre for Sport Security Journal.
Other speakers include Jason Kolbert, Head of Healthcare Research, Senior Managing Director and Biotechnology Analyst, Maxim Group; Manish Thakur, Managing Partner of Hudson Fairfax Group;
Marty Martin, CEO of Crane & Crane Consulting, who also has a background with the CIA, NSA, and the U.S. Army; Scott Greiper, President and Founding Partner of Secure Strategy Group; Scott Sacknoff, President of Spade Defense Index (NYSE: ^DXS); Janice Kephart, Founder and CEO of The Secure Identity and Biometrics Association (SIBA) and Phil Agcaoili, Chairman, Ponemon Institute Fellows Co-founding Member, Cloud Security Alliance Board Member, Mobile Active Defense.
Visit the conference page to learn more and sign up:
http://www.investorideas.com/Conference
Investors, media and industry service providers: Register here free: http://www.investorideas.com/Conference/Conference-Registration.asp
Media Partners:
Media partners include www.SecuritySolutionsWatch.com , a breaking news site covering new security solutions and business trends; SecurityStockWatch.com for investors following the sector; www.Wallstreetcalendar.com , informing the institutional investment community; Australian Security Magazine ( http://www.australiansecuritymagazine.com.au/ ); Global Security Finance ( www.globalsecurityfinance.com ), an online daily news and data service covering the physical, cyber and identity security and defense sectors; Hedge Connection ( https://www.hedgeconnection.com ), an interactive, web-based marketing tool available to hedge funds and investors; www.biometricupdate.com and http://www.biometricstechnologywatch.com/.
About InvestorIdeas.com: www.investorideas.com
InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense and security, renewable energy, food and beverage stocks and Latin American stocks.
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894 . Global investors must adhere to regulations of each country
Presenting Companies Contact info:
Cali Van Zant cvanzant@investorideas.com 800. 665. 0411
Sponsorship info:
Eric Salvarezza esalvarezza@investorideas.com 631. 664. 1311
Media Partners: D. Van Zant dvanzant@investorideas.com 800. 665. 0411
800-665-0411 - Source: www.Investorideas.com

Biometric Stock Alert: NXT-ID, Inc. (OTCQB: NXTD) to Present MobileBio(TM) Suite of Biometric Solutions at Defense and Security Conference March 11th New York

SHELTON, CT - March 4, 2014 (Investorideas.com Newswire) NXT-ID, Inc. (OTCQB: NXTD) a biometrics company focused on the growing m-commerce market, announces it will be presenting at the Defense and Security Conference, "Game Changing Technologies," to be held in New York on March 11th at The New York Hilton Midtown. The live conference will also be featured on a streaming live news and syndication platform to global media and industry followers.

The Company will join leading experts including Janice Kephart, Founder and CEO of The Secure Identity and Biometrics Association (SIBA) and cybersecurity expert and counterterrorism analyst Roger Cressey, Partner with Liberty Group.
Gino Pereira, Chief Executive Officer of NXT-ID, Inc. will discuss the company's innovative MobileBio™ suite of biometric solutions including its soon to be released Wocket™, a next generation smart wallet designed to replace all the cards in your wallet, with no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval.
The presentation will also feature the company's 3D facial recognition technology.
Speakers and presenters includes Michael Balboni, Former New York State Senator and Founder of RedLand Strategies, Mr. Lester Quintana, Senior Vice President for Consulting Services, Cellucci Associates, Inc., Kris Tuttle, Director of Research for SoundView Technology Group; cybersecurity expert and counterterrorism analyst Roger Cressey, Partner with Liberty Group Ventures; and Kiersten Todt, President and Managing Partner of Liberty Group Ventures, Marty Martin, CEO of Crane & Crane Consulting, who also has a background with the CIA, NSA, and the U.S. Army; Scott Greiper, President and Founding Partner of Secure Strategy Group; Scott Sacknoff, President of Spade Defense Index, Janice Kephart, Founder and CEO of The Secure Identity and Biometrics Association (SIBA) and Phil Agcaoili, Chairman, Ponemon Institute Fellows Co-founding Member, Cloud Security Alliance Board Member, Mobile Active Defense.
The one-day agenda will include a financial panel, an industry panel that includes some of the brightest minds within the sector, and presenting companies showcasing their innovative technologies. Attendance to this conference is free to all media, investors and industry service providers.

Tuesday, March 11, 2014
The New York Hilton Midtown
1335 Avenue of the Americas, New York, NY 10019
8:00 - 9:00 AM Registration & Networking
12:00 - 12:25 PM NXT-ID (OTCQB: NXTD) (May be slight changes in time)
12:30 - 5:25 PM Presenting companies and speakers
5:30 PM Closing Remarks
Speaker: Lester Quintana, Cellucci Associates, Inc.
5:45 - 7:15PM Cocktail Reception

Register and attend free or online: (limited seats available) http://www.investorideas.com/Conference/Conference-Registration.asp

Conference info: http://www.investorideas.com/Conference/

The Wocket product FAQ is available to consumers and media at http://www.thewocket.com/ and http://www.wocketwallet.com/.
Interested consumers can also sign up for product info and news alerts in anticipation of the product launch.
About NXT- ID Inc. - Mobile Security for a Mobile World
NXT-ID, Inc.'s (OTCQB: NXTD) innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms led by the Wocket™; a next generation smart wallet designed to replace all the cards in your wallet, no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval. http://www.thewocket.com/
NXT-ID' wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/
Forward-Looking Statements for NXT-ID
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.
Contact:
Investor Inquiries:
Kirin Smith
ProActive Capital Group
Direct: 646 863 6519
800 665-0411
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: November 2013 :Investorideas is compensated by NXTD: five thousand per month for news publication and syndication and is long 144 shares from previous services
More info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Security News Alert: Michael Balboni, Former New York State Senator and Founder of RedLand Strategies to Open Investorideas.com Security Conference - March 11th in New York; Mr. Lester Quintana, Senior Vice President of Cellucci Associates, Inc. to Provide Closing Remarks

New York, NY - March 3, 2014 (www.investorideas.com newswire) Investorideas.com, an investor research and news portal covering leading sectors including technology and defense, announces new speakers and presenters for its upcoming Security and Defense Conference, “Game Changing Technologies: The Face and Future of Security”, to be held both live in New York and online on March 11, 2014.

Michael Balboni, Former New York State Senator and Founder of RedLand Strategies, Inc. will open the conference agenda at 9:00 a.m. following networking and registration. Mr. Balboni was First Chairman of the Senate Homeland Security Committee and as NYS Senator wrote nearly all of the major laws relating to Homeland Security for New York State.
Also added to the speaker list and closing the conference is Mr. Lester Quintana, Senior Vice President for Consulting Services, Cellucci Associates, Inc. Mr. Quintana is a dynamic high-technology Business Executive with a strategic business and tactical operations background; he has held key positions in the Department of Defense, Department of Homeland Security, and other agencies. He has been engaged in Russia, States of the Former Soviet Union, Kuwait, Iraq, and globally sensitive locations.
The additional presenting company is Silanis, a company that has been providing secure electronic signature solutions to government for over 15 years, and understands the unique security and signing needs of Federal DoD and civilian agencies, as well as state and local governments(see more below).
The theme of the conference is ‘Game Changing Technologies: The Face and Future of Security’ and will be discussing developments in biodefense, biometrics including fingerprint, voice and facial recognition, cyber security and other leading edge technologies. Speakers and presenters will discuss how these issues impact individuals, corporations and governments globally.
The day’s agenda will include a financial panel, an industry panel that includes some of the brightest minds within the sector, and presenting companies showcasing their innovative technologies. Attendance to this conference is free to all media, investors and industry service providers.
This is one of the best represented conferences in terms of industry expertise, sector knowledge and innovation and will be game-changing for everyone that attends.
When /where:
Tuesday, March 11, 2014, The New York Hilton Midtown, New York City (1335 Avenue of the Americas, New York, NY 10019) and Online.
Conference info:
http://www.investorideas.com/Conference/
Media, Investors, Service Providers Attend and Register free: http://www.investorideas.com/Conference/Conference-Registration.asp
Agenda:

8:00 – 9:00AM	Registration & Networking
9:00 - 9:20AM	What is the Key to Staying Ahead?
Featured Speaker: MICHAEL BALBONI, Former New York State Senator; Founder RedLand Strategies, Inc.
Full day of speakers and presenting companies followed by:
5:30PM	Closing Remarks SPEAKER: LESTER QUINTANA, Cellucci Associates, Inc.
5:45 – 7:15PM	Cocktail Reception

See full agenda at http://www.investorideas.com/Conference/
New Presenting Company:
Silanis Technology: www.silanis.com
Businesses and government organizations of all sizes choose Silanis Technology when electronic signatures matter. With more than 600 million documents processed every year, Silanis eSignLive™ is the most widely used esignaturesolution around the world. Thousands of organizations, big and small, including leading banks, insurers, credit providers, pharmaceutical and government agencies trust eSignLive as their platform to make business digital. Silanis has been providing secure electronic signature solutions to government for over 15 years, and understands the unique security and signing needs of Federal DoD and civilian agencies, as well as state and local governments. Siilanis stands behind the longest running implementation of esignatures in the US government, and the largest signature initiative ever undertaken in government. Organizations that have standardized on Silanis include the US Joint Chiefs of Staff; the US Army with an enterprise license for 1.6 million personnel; and the General Services Administration (GSA), which mandated the use of esignatures for GSA Schedules contracts.
New speakers added:
Michael Balboni, Founder of RedLand Strategies http://www.redlandstrategies.com/
Founded by the Honorable Senator Michael Balboni:

• First Chairman of the Senate Homeland Security Committee.
• As NYS Senator, wrote nearly all of the major laws relating to Homeland Security for New York State.
• Deputy Secretary for Public Safety and Homeland Security Advisor for New York State, under two governors.
• Oversaw creation of: New York Alerts, Critical Infrastructure Suspicious Activity Reporting system for the State.
• Senior Fellow with the Homeland Security Policy Institute (HSPI) at George Washington University.
• Serves on the Spending and Government Efficiency (SAGE) Commission as well as on several homeland security think tanks, charitable boards dealing with public health.
• Regular contributor as a terrorism expert on national and local television and print media.

RedLand Strategies specializes in Homeland Security, Crisis & Emergency Management, Government Relations, Political Strategy, Transportation, and Financial Industries.
We leverage governmental and corporate relationships to generate sales opportunities and effective solutions to today's complex problems in both the private and public sectors
Mr. Lester Quintana, Senior Vice President for Consulting Services, Cellucci Associates, Inc. http://www.cellucciassociates.com/
Mr. Quintana is a dynamic high-technology Business Executive with a strategic business and tactical operations background; he has held key positions in the Department of Defense, Department of Homeland Security, and other agencies. He has been engaged in Russia, States of the Former Soviet Union, Kuwait, Iraq, and globally sensitive locations.
Mr. Quintana's areas of expertise include identifying commercial emerging technologies and providing them with strategic roadmaps with funding sources. He also provides executable strategic market penetration plans with emphasis on profitable growth, in-depth market analysis, and teaming agreements/negotiations. Most importantly, he has directly contributed to national security at the diplomatic level throughout the vast majority of the Russian Federation from Moscow to Siberia, to include states of the Former Soviet Union. While at the Department of Homeland Security, U.S. Coast Guard, he received numerous commendations for his homeland security efforts.
More info: http://www.investorideas.com/Conference/Speakers-More-Info.asp
The growing list of speakers and presenters includes Kris Tuttle, Director of Research for SoundView Technology Group; cybersecurity expert and counterterrorism analyst Roger Cressey*, Partner with Liberty Group Ventures; and Kiersten Todt**, President and Managing Partner of Liberty Group Ventures.
*From 2004 - 2013, Roger Cressey served as an on-air counterterrorism analyst with NBC News, appearing frequently on NBC Nightly News, The Today Show, MSNBC and CNBC.
**Ms. Todt has commented on homeland security and sport security issues in multiple media outlets, including MSNBC, NPR, Bloomberg, and The Wall Street Journal. Her work on sport security has been published in two editions of The International Centre for Sport Security Journal.
Other speakers include Jason Kolbert, Head of Healthcare Research, Senior Managing Director and Biotechnology Analyst, Maxim Group; Manish Thakur, Managing Partner of Hudson Fairfax Group;
Marty Martin, CEO of Crane & Crane Consulting, who also has a background with the CIA, NSA, and the U.S. Army; Scott Greiper, President and Founding Partner of Secure Strategy Group; Scott Sacknoff, President of Spade Defense Index (NYSE: ^DXS); Janice Kephart, Founder and CEO of The Secure Identity and Biometrics Association (SIBA) and Phil Agcaoili, Chairman, Ponemon Institute Fellows Co-founding Member, Cloud Security Alliance Board Member, Mobile Active Defense.
Presenting Companies:
See more companies: http://www.investorideas.com/Conference/Companies.asp
Visit the conference page to learn more and sign up:
http://www.investorideas.com/Conference
Investors, media and industry service providers: Register here free: http://www.investorideas.com/Conference/Conference-Registration.asp
Media Partners:
Media partners include www.SecuritySolutionsWatch.com , a breaking news site covering new security solutions and business trends; SecurityStockWatch.com for investors following the sector; www.Wallstreetcalendar.com , informing the institutional investment community; Australian Security Magazine ( http://www.australiansecuritymagazine.com.au/ ); Global Security Finance ( www.globalsecurityfinance.com ), an online daily news and data service covering the physical, cyber and identity security and defense sectors; Hedge Connection ( https://www.hedgeconnection.com ), an interactive, web-based marketing tool available to hedge funds and investors; www.biometricupdate.com and http://www.biometricstechnologywatch.com/ .
About InvestorIdeas.com: www.investorideas.com
InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense and security, renewable energy, food and beverage stocks and Latin American stocks.
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894 . Global investors must adhere to regulations of each country
Presenting Companies Contact info:
Cali Van Zant cvanzant@investorideas.com 800. 665. 0411
Sponsorship info:
Eric Salvarezza esalvarezza@investorideas.com 631. 664. 1311
Media Partners: D. Van Zant dvanzant@investorideas.com 800. 665. 0411
800-665-0411 - Source: www.Investorideas.com

Breaking News: Award winning producer Chad A. Verdi to produce three feature films over the next 10 months beginning with Bad Hurt and ending with Bleed For This

EAST GREENWICH, RI - February 26, 2014 (Investorideas.com Newswire) Verdi Productions and The Woodhaven Production Company are pleased to announce that award winning producer Chad A. Verdi will produce three feature films over the next 10 months. Verdi is now teamed with Oscar-winner Martin Scorsese (THE DEPARTED, GOODFELLAS) and Oscar nominee Emma Tillinger Koskoff (THE DEPARTED, THE WOLF OF WALL STREET) on two of his next three films.

The first film that Verdi and his wife Michelle will executive produce is titled Bad Hurt. Bad Hurt is currently being filmed in NY with principal photography ending in mid- March. Bad hurt, a drama which follows the struggles of a blue collar American family, is directed by Mark Kemble off his screenplay which he wrote alongside Jamieson Stern. The film stars, Theo Rossi ("Sons of Anarchy", "Cloverfield", "Red Sands") Karen Allen("Indiana Jones, Raiders of the Lost Ark", "The Perfect Storm","Scrooged") and Ashley Williams ("Margin Call", "Something Borrowed", "How I Met Your Mother").
The second feature is titled Almost Mercy and was written by B. Dolan and Tom DeNucci. Verdi tapped DeNucci to direct and produce. Sam Eilertsen will be the director of photography. The film tells the tale of a quaint little town with a dark secret. We focus on two outcasts, Jackson and Emil, victims of the town’s seedy underbelly. Ticking time bombs, they are seeking revenge. It's a race to see who will unravel first. Dealing with issues that are far too common in our society, the film focuses on a new breed of terror. A fear that is now closer to home than ever imagined.
The film stars Kane Hodder ("Jason X", "Monster", "Hatchet"), best known for his portrayal of Jason Voorhees in the "Friday the 13th" franchise, who will play Coach Elwood, a seedy, overly aggressive gym teacher, driven by self-help books and his obsession with inflicting mental pain on his students. The great Bill Moseley ("The Devil's Rejects", "Night of the Living Dead", "Army of Darkness") will play Pastor Johnson, an overzealous preacher, who's got the whole town fooled.
Verdi stated, "Tom DeNucci has directed two great films for us and we expect that he will repeat this again." Verdi added, “DeNucci was elevated to producer on this feature film because of all his hard work and dedication to the project. I am very happy that the flowing producers and ex-producers will be joining Tommy and I in association with LDI unlimited, David Gere, David Lussier as producers and, Sherry Lussier, Michael Cole, Taylor Van Zant, Seth Rosenblit with Michelle Verdi as ex-producer and music supervisor.
The third film is titled BLEED FOR THIS and tells the true-life story of 5-time world champion Rhode Island boxer Vinny Pazienza; as he recovers from a near fatal car accident that left him with a broken neck. He then goes on to win three additional world boxing titles, one of the most incredible and dramatic comebacks in sports history.
Golden Globe nominated actor Aaron Eckhart, (THE DARK KNIGHT, OLYMPUS HAS FALLEN, I, FRANKENSTEIN) will take on the role of Paz's boxing trainer, Kevin Rooney. Rooney was the trainer to Mike Tyson when Tyson won his first heavyweight championship. Rooney had a major role in changing Vinny's boxing style that lead him to become one of only two boxers ever to win titles in the lightweight and junior middle weight class in 1991. The other boxer was Roberto Duran who Vinny fought twice with victories for Vinny in both fights.
Miles Teller (THE FANTASTIC FOUR, 21 & OVER, PROJECT X), currently starring in THAT AWKWARD MOMENT, in theaters now, will take on the role of Vinny Paz.
The powerhouse team is led by writer/director Ben Younger (BOILER ROOM, PRIME), Oscar-winner Martin Scorsese (THE DEPARTED, GOODFELLAS), Oscar-winning producer Bruce Cohen (AMERICAN BEAUTY, SILVER LININGS PLAYBOOK), Emma Tillinger Koskoff (THE DEPARTED, THE WOLF OF WALL STREET), Noah Kraft (LOOSIES), award-winning RI producer Chad A. Verdi (LOOSIES, A BET'S A BET, BAD HURT), Michelle Verdi (LOOSIES, A BET'S A BET, BAD HURT ).
Verdi stated, "I am very excited about taking on the challenges of producing these three films over the next 10 months. It's a very special time for my wife Michelle and I, and our whole production team. It's not often a production company like ours has the luxury of turning down fully funded projects. We are currently booked through 2016 and it's a great position to be in."
Verdi's home-grown East Greenwich Company, Verdi Productions/Woodhaven Production Company, has produced six feature films in Rhode Island over the past four years. BLEED FOR THIS is his most ambitious project to date, with an estimated budget between $10,000,000 and $20,000,000.
Verdi added, "My producing partners Noah Kraft, my wife Michelle, and I got involved in the film business in 2009 with one purpose: to have the story of Vinny Paz told. The best thing that ever happened to this project was Ben Younger coming on board to write and direct BLEED FOR THIS. BLEED FOR THIS is Ben's vision and with the support of Martin Scorsese, Bruce Cohen and Emma Tillinger Koskoff, this film is destined for greatness. I was introduced to Martin and Emma through Senator Sheldon Whitehouse, who has been instrumental in helping me develop these projects." Verdi added, "Writer/director Tom DeNucci will be brought on board as a consultant to the project. Tom will be working directly for me over the next several months in order for us to be ready to shoot sometime this summer."
CONTACT INFORMATION
For more information, please contact
Chad A. Verdi
http://www.imdb.com/name/nm3838148/?ref_=fn_al_nm_1
Mary Larsen
Executive Coordinator
401.447.7403
Verdi Productions & The Woodhaven Production Company
253 Main Street East Greenwich, RI 02818
Verdifilms.com, Woodhavenfilms.com

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces Agreement with DaVita Clinical Research

SAN DIEGO - February 26, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that that it has reached an agreement in principle with DaVita Clinical Research® (DCR) to provide clinical management services that will support forthcoming studies of the Aethlon Hemopurifier®. The Hemopurifier® is a first-in-class therapeutic device that targets the rapid elimination of circulating viruses and tumor-secreted exosomes that suppress the immune system of cancer patients.

DCR is a specialty contract research organization (CRO) with experience in conducting more than 300 early phase clinical trials. As a subsidiary of DaVita Healthcare Partners, DCR has access to one third of the total US end-stage renal disease (ESRD) patient population and maintains a network that exceeds 150 investigative physicians practices at more than 250 clinical sites.
Aethlon previously disclosed that the United States Food and Drug Administration (FDA) had approved an Investigational Device Exemption (IDE) that allows the Company to initiate human feasibility studies of the Aethlon Hemopurifier® in the United States. Under the feasibility study protocol, Aethlon is to enroll ten ESRD patients infected with Hepatitis C virus (HCV) to demonstrate the safety of Hemopurifier therapy. Successful completion of the feasibility study will set the stage for Aethlon to conduct pivotal studies required for market clearance to treat HCV and potentially other disease indications.
"Not long after the FDA had cleared our IDE, we were presented an opportunity to advance a clinical relationship with DaVita Clinical Research,” stated Aethlon Chairman and CEO, Jim Joyce. "As a result, we have transitioned our clinical plan from working with a single-site institute to working with a single institute that has a multitude of clinical sites across the United States. Beyond maintaining the resources necessary to advance our feasibility study, DaVita's proven extracorporeal expertise, patient accrual capabilities and expansive clinical infrastructure provide a foundation to support our long-term vision of treating a variety of infectious disease and cancer indications."
Aethlon further disclosed that the DCR agreement was entered into on a non-exclusive basis and is pending the completion of a definitive agreement, which will include a work order describing the full scope of services to be provided by DCR to Aethlon Medical.
DaVita Clinical Research is a wholly owned subsidiary of DaVita HealthCare Partners (NYSE:DVA), a Fortune 500 company and parent company of DaVita and HealthCare Partners. DaVita is a leading provider of kidney care in the United States and abroad, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. As of December 31, 2013, DaVita operated or provided administrative services at 2,074 outpatient dialysis centers in the United States serving approximately 168,000 patients, and at 73 centers in ten countries outside of the United States. HealthCare Partners(R) manages and operates medical groups and affiliated physician networks in California, Nevada, Florida, Arizona and New Mexico in its pursuit to deliver excellent-quality health care in a dignified and compassionate manner. As of December 31, 2013, HealthCare Partners provided integrated care management for approximately 765,000 managed care patients. For more information, please visit DaVitaHealthCarePartners.com.
About Aethlon Medical, Inc.
Aethlon Medical creates innovative medical devices to address life-threatening diseases. The Aethlon ADAPT™ (Adaptive Dialysis-like Affinity Platform Technology) establishes the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory system of treated patients. The lead Aethlon ADAPT™ product is the Hemopurifier®, a device that addresses a broad-spectrum of viral pathogens as well as tumorsecreted exosomes that suppress the immune system of cancer patients. Aethlon is also operating under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing exosome-based strategies to diagnose and monitor cancer and infectious disease progression. Additional information can be found at www.AethlonMedical.com
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's existing or future clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar

Biotech/Pharma Companies Targeting Pancreatic Cancer: (SBFM), (NLNK), (LLY, NYSE), (CELG)

Point Roberts, WA, New York, NY - February 26, 2014 (Investorideas.com Biotech Newswire) Investorideas.com global news source covering leading sectors including biotech and pharma reports on companies in the sector targeting pancreatic cancer. Companies include NewLink Genetics (NLNK), Sunshine Biopharma Inc. ( OTCBB: SBFM ), Eli Lilly and Company (NYSE: LLY) and Celgene (NASDAQ::CELG).

According to the Pancreatic Cancer Action Network "Pancreatic cancer is currently the fourth leading cause of cancer death in the United States, and is anticipated to become the second by 2020.”
In their fact sheet they also note " Pancreatic cancer is one of the nation's deadliest cancers with a five-year relative survival rate of just 6 percent. An estimated 73 percent of patients will die in the first year of diagnosis. In 2014, an estimated 46,420 people will be diagnosed with pancreatic cancer in the United States, and approximately 39,590 will die from the disease.”
Decision Resources (http://www.decisionresources.com/),one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the pancreatic cancer therapy market will nearly double to $1.3 billion in 2022, owing to the launch and rapid uptake of three high-priced agents—Celgene (NASDAQ::CELG)/Taiho's Abraxane, Onconova Therapeutics/Baxter International/SymBio Pharmaceuticals' Estybon and Merrimack Pharmaceuticals' MM-398 (a novel formulation of irinotecan). Even though these agents do not substantially improve the overall survival of pancreatic cancer patients, they will have a significant impact on current treatment.
The Pharmacor Pancreatic Cancer report also finds that significant commercial reward awaits developers of therapies that are more effective and better tolerated than the FOLFIRINOX regimen in this disease, as the need for efficacious, well-tolerated therapies will remain through 2022.
NewLink Genetics (NASDAQ: NLNK) has been of the top gainers for 2014,gaining over 90%.NewLink's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications.
Their product, RAlgenpantucel-L is an investigational HyperAcute™ immunotherapy for pancreatic cancer. The product consists of 2 pancreatic cancer cell lines (HAPa-1 and HAPa-2) that have been genetically modified to express alpha-gal carbohydrates on cell surface molecules.1 Upon injection into the patient, the alpha-gal stimulates an immune response against pancreatic cancer-specific antigens in the tumor cell lines. The patient's immune system then targets its own pancreatic cancer cells, destroying them.1 In the adjuvant setting, the immune response targets and eradicates residual tumor cells in conjunction with chemotherapy and chemoradiation.1,2
Algenpantucel-L is currently being studied in combination with standard of care in two phase 3 trials:
Last fall the company reported greater than expected responses to follow-on chemotherapy after treatment with algenpantucel-L or tergenpumatucel-L HyperAcute immunotherapy. Three pancreatic cancer patients were followed for response to subsequent salvage chemotherapy treatment after progressing on algenpantucel-L therapy. All three patients experienced durable (12-36 months), complete responses.
Sunshine Biopharma Inc. ( OTCBB: SBFM ), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, recently announced that it is targeting pancreatic cancer as second indication for its leading compound, Adva-27a.
As previously announced, Adva-27a was found to be effective at killing Pancreatic Cancer Cells in vitro. Based on initial data, the company is now advancing research using Adva-27a for pancreatic cancer treatment.
The initial study, as reported in June 2013, was carried out in the very aggressive Pancreatic Cancer cell line, Panc-1. Adva-27a was able to kill these cells with an IC50 of less than 4 micromolar, a pharmacologically very favorable drug concentration.
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under US patent number 8,236,935.
The Company also announced that it has initiated the construction of mouse xenograft models for pancreatic cancer as part of the plans of positioning Adva-27a for clinical development for pancreatic cancer in parallel with multidrug resistant breast cancer. The work is being conducted in collaboration with Sunshine Biopharma's parent company, Advanomics Corporation, the co-recipient of $1.45 million in research grants in Canada. As previously announced (see press release dated June 4, 2013), Adva-27a, a Topoisomerase II inhibitor, was found to be effective at destroying cells of the very aggressive pancreatic cancer cell line, Panc-1.
"Conducting tests in pancreatic cancer xenograft models is the next step in our preparations for doing parallel breast cancer and pancreatic cancer clinical trials of Adva-27a," said Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma. "Pancreatic cancer is an extremely aggressive form of cancer with essentially no effective treatment options available today. We are heartened by the prospects that Adva-27a could become an effective therapy for patients suffering this deadly form of cancer."
According to Global Industry Analysts, Inc. in their recent report, "Eli Lilly's (LLY:NYSE) Gemzar (Gemcitabine) is the current gold standard of care for locally advanced and metastatic disease, with a dominance that is undisputed despite a median survival of less than 6 months and rate of one-year survival of around 18%, as stated by the new market research report on Pancreatic cancer drugs. Though the odds of survival are somewhat better in other forms of cancer, the rate of five-year survival for the most common form of pancreatic cancer, Adenocarcinoma of the pancreas is less than 5%, with majority of patients surviving just a few months. "
www.Investorideas.com - Big ideas for Global Investors
Investorideas.com is a global news source and resource base for investors following tech stocks, biometric stocks, water stocks, biotech stocks, energy stocks, mining stocks, renewable energy stocks, nanotech and Latin American stocks.
Follow Investorideas.com on Twitter  
Follow Investorideas.com on Facebook  
Follow Investorideas.com News on Linkedin.com/today
Sign up for free news alerts and get free research tools:
http://www.investorideas.com/Resources/Newsletter.asp
Join us and become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in leading sectors
http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investor ideas is protected by copyright laws other than syndication rights. Investor ideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Disclosure investor ideas has been compensated with 144 shares for news and content publication ( 100,000 per three month period)
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
800-665-0411 - Source - www.Investorideas.com